Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
affix, AgreementSM, Agriculture, Annex, API, ASCO, aspire, attain, attendant, attrition, axicabtagene, baseline, BCMA, bench, Bogle, bortezomib, Breyanzi, Britain, brought, Canada, Carlo, CDE, CE, Ceiling, CellCentric, check, China, ciloleucel, CJEU, clarification, Columbia, combat, condensed, constitutionality, Council, cut, cycle, cyclophosphamide, daratumumab, Dartmouth, deep, deficiency, dismissed, England, EPIC, EPIsode, equitable, evidentiary, expiry, explicit, Fate, FCA, Florida, Foghorn, forgoing, Forma, foster, FSS, fulfill, fundamentally, furthest, Gilead, gouging, Great, Gritstone, headcount, Hengrui, HMR, Hong, Hutchison, HutchMed, hybrid, hydrobromide, ID, IEC, imid, immigration, inevitable, inflation, instability, Ireland, issuable, IVDD, IVDR, ixazomib, Jiangsu, job, Kite, Kong, kymriah, landscape, legitimize, lenalidomide, lisocabtagene, loncastuximab, lowest, mAb, Macau, Maine, mainland, maraleucel, McKesson, MDR, meantime, MediTech, MEI, Mexico, MHRA, Millennium, MM, MMSET, Monjuvi, Monte, morale, mosunetuzumab, myeloma, neuroendocrine, Ninlaro, occasional, Onxeo, outweigh, parsaclisib, payer, persist, pilot, polatuzumab, polycomb, pomalidomide, Pomalyst, preexisting, prerequisite, presidential, problem, proteasome, PSA, radiographic, refine, refined, registry, reinforce, released, remeasured, repressive, reprioritization, rescind, rescinded, resignation, Retail, revoked, Richon, RTF, SA, Sarclisa, Scotland, screening, Senate, shelf, Shield, SI, signaled, SIP, standing, startup, subtype, succeeding, sue, tafasitamab, Taiwan, TAZERIK, tenant, tesirine, Thalidomide, thalomid, tie, tisagenlecleucel, traceability, traditional, Tricare, turnover, uncommon, uniform, unrest, Variation, vedotin, Velcade, Vermont, vincristine, voluntarily, waiting, Welfare, widespread, withdrawn, workflow, workforce, xarfilzomib, yescarta, Zandelisib, Zynlonta
Removed:
acute, Allen, AMT, Andrew, approvable, Ardelyx, ARIAD, atezolizumab, attributed, biochemistry, blended, breast, career, Centocor, checkpoint, children, CNS, continually, counterparty, CRADA, curve, determinable, dissemination, Division, dysregulated, encompassing, ESPP, Ethicon, fifteen, Fifty, focusing, formula, Genentech, genomic, Georgia, guaranteed, Head, histiocytic, historically, idealisib, immunotherapy, Janssen, leukemia, linked, lymphoblastic, Manager, mandated, match, Mine, myeloid, NCI, niraparib, objective, opening, Ortho, ovarian, oversaw, peer, Pennsylvania, permitted, pinometostat, Plattsburgh, practical, reclassification, reclassified, refundable, retained, reversed, RIVOT, RMS, Sanofi, serving, session, simplified, summarize, Supplementary, Synageva, unavailable, Unresolved, unsatisfactory, Wharton, worked, ZEJULA
Filing tables
Filing exhibits
Related press release
Associated EPZM transcripts
EPZM similar filings
Filing view
External links